- Home
- BLNK vs AGEN Comparison
BLNK vs AGEN Comparison
Compare BLNK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- AGEN
- Stock Information
- Founded
- BLNK 2009
- AGEN 1994
- Country
- BLNK United States
- AGEN United States
- Employees
- BLNK N/A
- AGEN N/A
- Industry
- BLNK Industrial Specialties
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLNK Consumer Discretionary
- AGEN Health Care
- Exchange
- BLNK Nasdaq
- AGEN Nasdaq
- Market Cap
- BLNK 105.2M
- AGEN 96.2M
- IPO Year
- BLNK N/A
- AGEN 2000
- Fundamental
- Price
- BLNK $0.92
- AGEN $1.51
- Analyst Decision
- BLNK Buy
- AGEN Buy
- Analyst Count
- BLNK 8
- AGEN 4
- Target Price
- BLNK $3.31
- AGEN $8.00
- AVG Volume (30 Days)
- BLNK 3.6M
- AGEN 484.8K
- Earning Date
- BLNK 03-13-2025
- AGEN 03-11-2025
- Dividend Yield
- BLNK N/A
- AGEN N/A
- EPS Growth
- BLNK N/A
- AGEN N/A
- EPS
- BLNK N/A
- AGEN N/A
- Revenue
- BLNK $126,197,000.00
- AGEN $103,463,000.00
- Revenue This Year
- BLNK $25.90
- AGEN $32.21
- Revenue Next Year
- BLNK $35.81
- AGEN N/A
- P/E Ratio
- BLNK N/A
- AGEN N/A
- Revenue Growth
- BLNK N/A
- AGEN N/A
- 52 Week Low
- BLNK $0.86
- AGEN $1.44
- 52 Week High
- BLNK $3.75
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- BLNK 39.97
- AGEN 21.95
- Support Level
- BLNK $0.98
- AGEN $1.55
- Resistance Level
- BLNK $1.05
- AGEN $1.77
- Average True Range (ATR)
- BLNK 0.07
- AGEN 0.14
- MACD
- BLNK 0.00
- AGEN 0.02
- Stochastic Oscillator
- BLNK 25.21
- AGEN 9.85
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).